Hydrogenology
Hydrogenology editorial study record

Hydrogen Gas Inhalation Improved Intestinal Microbiota in Ulcerative Colitis: A Randomised Double-Blind Placebo-Controlled Trial

Maruyama T et al. · Biomedicines. 2025;13(8):1799.

HumanInhaled H₂Published 2025
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Randomized double-blind placebo-controlled pilot trial

Research topic

Gastrointestinal health

Administration classification

Inhaled H₂

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Adults with active ulcerative colitis continuing standard treatment

Sample

10 participants: H₂ n=5, placebo n=5

Duration

4 hours/day for 8 weeks

Intervention

Hydrogen in air inhaled at home for 4 hours/day

Hydrogen form

H₂ in mixed air — H₂ only was generated; this was not Brown’s gas and no O₂ stream was co-delivered.

H₂ specification

5–6% H₂ in a total airflow of 4 L/min.

H₂ flow

200–240 mL/min H₂, calculated as 5–6% of the reported 4,000 mL/min total flow.

O₂ delivered with H₂

No separate O₂ stream was reported; ordinary air supplied the background oxygen.

Comparator

Air from a visually identical placebo machine

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Clinical and endoscopic indices, microbiome diversity and functional-gene analyses, safety

Reported result

The trial found no clear therapeutic effect on ulcerative colitis. Alpha diversity was not significant (p=0.19); beta-diversity change was reported at p=0.02. No inhalation-related adverse events were reported.

Results-extraction completeness

Methods, flow, main clinical and microbiome results, early stopping and funding checked in the free full text.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Only five participants per arm, many microbiome comparisons, standard therapies continued, and recruitment stopped after interim review because clear clinical improvement was absent. MiZ Co., the device manufacturer, funded the study.

Applies directly to

Adults with active ulcerative colitis meeting this pilot trial’s criteria.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 40868053 · DOI: 10.3390/biomedicines13081799

Publisher access

Open-access article.

Extraction basis

Free full text on PMC and publisher page; identifiers cross-checked in PubMed.

Record revision

2026-08-10